Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00223977 · ClinicalTrials.gov registry record · Phase 2

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

A Phase 2 study of Iron Deficiency Anemia, sponsored by Watson Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
146
Enrollment target
20
Study locations

NCT00223977: Completed Phase 2 study of Iron Deficiency Anemia, sponsored by Watson Pharmaceuticals.

NCT00223977 is a Phase 2 study of Iron Deficiency Anemia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 146 participants, below the 188-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00223977, a Phase 2 study of Iron Deficiency Anemia, has completed, sponsored by Watson Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
146 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.

Primary Outcome

Change from baseline to 1 week after the last oral iron dose or 2 weeks after the last sodium ferric gluconate injection

Conditions Studied

Interventions

  • DRUG Sodium Ferric Gluconate Complex
  • DRUG Oral Iron

Study Locations (20)

California

  • - Los Angeles
  • - Torrance

Massachusetts

  • - Springfield
  • - Worcester

North Carolina

  • - Chapel Hill
  • - Winston-Salem

Alabama

  • - Birmingham

Arizona

  • - Mesa

Connecticut

  • - New Haven

Illinois

  • - Evanston

Louisiana

  • - Shreveport

Trial Details

FieldValue
Enrollment Target 146 participants
Start Date 2003-12
Est. Completion 2008-02
Phase Phase 2
Watson Pharmaceuticals

28 total trials

What the finished NCT00223977 record still lists

NCT00223977 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 188-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (22% lower).

The record links to 1 condition, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 2 interventions - of which Sodium Ferric Gluconate Complex is the first listed.

NCT00223977 names 20 study sites across 17 states, led by California, Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00223977 about?

NCT00223977 is a clinical study titled "2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.". This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.

What is the current status of trial NCT00223977?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2003-12. Estimated completion is 2008-02.

What conditions does trial NCT00223977 study?

This clinical trial studies the following conditions: Iron Deficiency Anemia.

What interventions are being tested in trial NCT00223977?

The interventions under investigation include: Sodium Ferric Gluconate Complex (DRUG), Oral Iron (DRUG).

Who is sponsoring clinical trial NCT00223977?

This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00223977 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Iron Deficiency Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00223977's enrollment target sits among peer trials

146 5th of 24 higher than 20 of 24 other Iron Deficiency Anemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Iron Deficiency Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03490929 · 146 participants · Phase 4

    CEUS for Blunt Abdominal Trauma in Children

  • NCT04755062 · 146 participants · NA

    A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans

  • NCT04867954 · 146 participants

    Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

  • NCT05051618 · 146 participants · NA

    Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00223977, the US trial registry maintained by the National Library of Medicine. NCT00223977 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.